|
1
|
Vogt A, Schmid S, Heinimann K, Frick H,
Herrmann C, Cerny T and Omlin A: Multiple primary tumours:
Challenges and approaches, a review. ESMO Open. 2:e0001722017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Moertel CG, Dockerty MB and Baggenstoss
AH: Multiple primary malignant neoplasms. I. Introduction and
presentation of data. Cancer. 14:221–230. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Müller M, Li J, Giger R and Elicin O: Head
and neck cancer with synchronous nodules of the lung as a
diagnostic and therapeutic challenge-a systematic review. Oral
Oncol. 145:1065292023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dür C, Salmina C, Borner U, Giger R and
Nisa L: Relevance of intraparotid metastases in head and neck skin
squamous cell carcinoma. Laryngoscope. 131:788–793. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altundag K, Yalcin S, Ozkaya O and Guler
N: Synchronous squamous cell carcinoma of the stomach, the lung and
the skin. Onkologie. 27:291–293. 2004.PubMed/NCBI
|
|
6
|
Filippakis GM, Lagoudianakis EE,
Genetzakis M, Antonakis P, Papadima A, Boussiotou A, Katergiannakis
V and Manouras A: Squamous cell carcinoma arising in a mature
cystic teratoma of the ovary with synchronous invasive lobular
breast cancer: Case report. Eur J Gynaecol Oncol. 27:537–540.
2006.PubMed/NCBI
|
|
7
|
Studziński Z and Branicka D: The analysis
of coexistence of endometrial cancer with other malignant and
benign neoplasms with endometriosis. Ginekol Pol. 69:273–278.
1998.(In Polish). PubMed/NCBI
|
|
8
|
Corchado-Cobos R, García-Sancha N,
González-Sarmiento R, Pérez-Losada J and Cañueto J: Cutaneous
squamous cell carcinoma: From biology to therapy. Int J Mol Sci.
21:29562020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Que SKT, Zwald FO and Schmults CD:
Cutaneous squamous cell carcinoma: Incidence, risk factors,
diagnosis, and staging. J Am Acad Dermatol. 78:237–247. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang MS, Azin M and Demehri S: Cutaneous
squamous cell carcinoma: The frontier of cancer immunoprevention.
Annu Rev Pathol. 17:101–119. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alam M and Ratner D: Cutaneous
squamous-cell carcinoma. N Engl J Med. 344:975–983. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmitz L and Kanitakis J: Histological
classification of cutaneous squamous cell carcinomas with different
severity. J Eur Acad Dermatol Venereol. 33 (Suppl 8):S11–S15. 2019.
View Article : Google Scholar
|
|
13
|
Heath CR and Usatine RP: Squamous cell
carcinoma. Cutis. 112:97–98. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kallini JR, Hamed N and Khachemoune A:
Squamous cell carcinoma of the skin: Epidemiology, classification,
management, and novel trends. Int J Dermatol. 54:130–140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karagas MR, Nelson HH, Sehr P, Waterboer
T, Stukel TA, Andrew A, Green AC, Bavinck JN, Perry A, Spencer S,
et al: Human papillomavirus infection and incidence of squamous
cell and basal cell carcinomas of the skin. J Natl Cancer Inst.
98:389–395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Veness MJ: High-risk cutaneous squamous
cell carcinoma of the head and neck. J Biomed Biotechnol.
2007:805722007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schmults CD, Karia PS, Carter JB, Han J
and Qureshi AA: Factors predictive of recurrence and death from
cutaneous squamous cell carcinoma: A 10-year, single-institution
cohort study. JAMA Dermatol. 149:541–547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jambusaria-Pahlajani A, Miller CJ, Quon H,
Smith N, Klein RQ and Schmults CD: Surgical monotherapy versus
surgery plus adjuvant radiotherapy in high-risk cutaneous squamous
cell carcinoma: A systematic review of outcomes. Dermatol Surg.
35:574–585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weinberg AS, Ogle CA and Shim EK:
Metastatic cutaneous squamous cell carcinoma: An update. Dermatol
Surg. 33:885–899. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu GA and Lynn Su Chang A: Overall and
progression-free survival of stage 4 cutaneous squamous cell
carcinoma at a single large referral center. J Am Acad Dermatol.
73:165–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines©). Squamous Cell Skin Cancer, version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdfApril
3–2025
|
|
22
|
Rischin D, Khushalani NI, Schmults CD,
Guminski AD, Chang ALS, Lewis KD, Lim AML, Hernandez-Aya LF, Hughes
BGM, Schadendorf D, et al: Phase II study of cemiplimab in patients
(pts) with advanced cutaneous squamous cell carcinoma (CSCC):
Longer follow-up. J Clin Oncol. 38 (Suppl 15):S100182020.
View Article : Google Scholar
|
|
23
|
Grob JJ, Gonzalez R, Basset-Seguin N,
Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats JM,
Bauman JR, et al: Pembrolizumab monotherapy for recurrent or
metastatic cutaneous squamous cell carcinoma: A single-arm phase II
trial (KEYNOTE-629). J Clin Oncol. 38:2916–2925. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA;
WHO Classification of Tumours Editorial Board, : The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muto M, Hasebe T, Muro K, Boku N, Ohtsu A,
Fujii T, Ono M, Taijiri H, Mukai K and Yoshida S: Primary squamous
cell carcinoma of the stomach: A case report with a review of
Japanese and Western literature. Hepatogastroenterology.
46:3015–3018. 1999.PubMed/NCBI
|
|
26
|
Dursun M, Yaldiz M, Işikdoğan A, Yilmaz G,
Canoruç F, Ormeci N and Yilmaz S: Primary squamous cell carcinoma
of the stomach: A case report and review of the literature. Eur J
Gastroenterol Hepatol. 15:329–330. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mori M, Iwashita A and Enjoji M: Squamous
cell carcinoma of the stomach: Report of three cases. Am J
Gastroenterol. 81:339–342. 1986.PubMed/NCBI
|
|
28
|
Volpe CM, Hameer HR, Masetti P, Pell M,
Shaposhnikov YD and Doerr RJ: Squamous cell carcinoma of the
stomach. Am Surg. 61:1076–1078. 1995.PubMed/NCBI
|
|
29
|
He Y, Cui Y, Duan X, Liu C and Cai X:
Primary lung squamous cell carcinoma with gastric metastasis: A
case report. Thorac Cancer. 10:373–377. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oriuchi M, Uno K, Fujishima F, Takeuchi A,
Lee S, Hatta W, Asano N, Koike T, Imatani A and Masamune A: A rare
case of gastric squamous-cell carcinoma metastasized from the
cervix. Clin J Gastroenterol. 13:1062–1065. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reise-Filteau M, Carter M, DeCoste R and
Kohansal A: Metastasis of cutaneous squamous cell carcinoma to the
stomach: A rare entity. BMJ Case Rep. 13:e2387312020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Krolls SO and Hoffman S: Squamous cell
carcinoma of the oral soft tissues: A statistical analysis of
14,253 cases by age, sex, and race of patients. J Am Dent Assoc.
92:571–574. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chi AC, Day TA and Neville BW: Oral cavity
and oropharyngeal squamous cell carcinoma-an update. CA Cancer J
Clin. 65:401–421. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bornstein MM, Andreoni C, Meier T and
Leung YY: Squamous cell carcinoma of the gingiva mimicking
periodontal disease: A diagnostic challenge and therapeutic
dilemma. Int J Periodontics Restorative Dent. 38:253–259. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines©). Head and Neck Cancers, version 2.2025.
https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdfApril
3–2025
|
|
36
|
Will TA, Agarwal N and Petruzzelli GJ:
Oral cavity metastasis of renal cell carcinoma: A case report. J
Med Case Rep. 2:3132008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aguirre A, Rinaggio J and Diaz-Ordaz E:
Lingual metastasis of renal cell carcinoma. J Oral Maxillofac Surg.
54:344–346. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Magaki S, Hojat SA, Wei B, So A and Yong
WH: An Introduction to the performance of immunohistochemistry.
Methods Mol Biol. 1897:289–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin F and Chen Z: Standardization of
diagnostic immunohistochemistry: Literature review and geisinger
experience. Arch Pathol Lab Med. 138:1564–1577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bellizzi AM: An algorithmic
immunohistochemical approach to define tumor type and assign site
of origin. Adv Anat Pathol. 27:114–163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fitzgibbons PL, Bradley LA, Fatheree LA,
Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG,
Loykasek PA, Marolt MJ, et al: Principles of analytic validation of
immunohistochemical assays: Guideline from the College of American
pathologists pathology and laboratory quality center. Arch Pathol
Lab Med. 138:1432–1443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Linder S, Olofsson MH, Herrmann R and
Ulukaya E: Utilization of cytokeratin-based biomarkers for
pharmacodynamic studies. Expert Rev Mol Diagn. 10:353–359. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Moll R: Molecular diversity of
cytokeratins: Significance for cell and tumor differentiation. Acta
Histochem Suppl. 41:117–127. 1991.PubMed/NCBI
|
|
44
|
Nobre AR, Albergaria A and Schmitt F: p40:
A p63 isoform useful for lung cancer diagnosis-a review of the
physiological and pathological role of p63. Acta Cytol. 57:1–8.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bauml J, Seiwert TY, Pfister DG, Worden F,
Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al:
Pembrolizumab for platinum- and cetuximab-refractory head and neck
cancer: Results from a single-arm, phase II study. J Clin Oncol.
35:1542–1549. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Agalliu I, Gapstur S, Chen Z, Wang T,
Anderson RL, Teras L, Kreimer AR, Hayes RB, Freedman ND and Burk
RD: Associations of oral α-, β-, and γ-human papillomavirus types
with risk of incident head and neck cancer. JAMA Oncol. 2:599–606.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen X, Gao L, Sturgis EM, Liang Z, Zhu Y,
Xia X, Zhu X, Chen X, Li G and Gao Z: HPV16 DNA and integration in
normal and malignant epithelium: Implications for the etiology of
laryngeal squamous cell carcinoma. Ann Oncol. 28:1105–1110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fullerton ZH, Butler SS, Mahal BA,
Muralidhar V, Schoenfeld JD, Tishler RB and Margalit DN: Short-term
mortality risks among patients with oropharynx cancer by human
papillomavirus status. Cancer. 126:1424–1433. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Köbel M and Kang EY: The many uses of p53
immunohistochemistry in gynecological pathology: Proceedings of the
ISGyP companion society session at the 2020 USCAP Annual9 meeting.
Int J Gynecol Pathol. 40:32–40. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Jia H, Wu S, Ma G, Yang P, Li X, Zeng M,
Ji X and Xing X: p53 Immunohistochemistry staining patterns and
prognosis significance in 212 cases of non-endometrioid endometrial
cancer. Pathol Res Pract. 263:1555952024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vermij L, Léon-Castillo A, Singh N, Powell
ME, Edmondson RJ, Genestie C, Khaw P, Pyman J, McLachlin CM,
Ghatage P, et al: p53 immunohistochemistry in endometrial cancer:
Clinical and molecular correlates in the PORTEC-3 trial. Mod
Pathol. 35:1475–1483. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou C, Chen G, Huang Y, Zhou J, Lin L,
Feng J, Wang Z, Shu Y, Shi J, Hu Y, et al: Camrelizumab plus
carboplatin and pemetrexed versus chemotherapy alone in
chemotherapy-naive patients with advanced non-squamous
non-small-cell lung cancer (CameL): A randomised, open-label,
multicentre, phase 3 trial. Lancet Respir Med. 9:305–314. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y,
Chen Z, Chen J, Zhang H, Niu Z, Fan Q, et al: Camrelizumab versus
investigator's choice of chemotherapy as second-line therapy for
advanced or metastatic oesophageal squamous cell carcinoma
(ESCORT): A multicentre, randomised, open-label, phase 3 study.
Lancet Oncol. 21:832–842. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ju H, Wei D, Wu Y, Liu Y, Ding Q, Rui M,
Fan Z, Yao Y, Hu J and Ren G: A pilot study of camrelizumab with
docetaxel and cisplatin for the first line treatment in
recurrent/metastatic oral squamous cell carcinoma. MedComm (2020).
4:e3122023. View Article : Google Scholar : PubMed/NCBI
|
